Do you want to sell pictures online on social media without being censored? Try qrush.com!
Iron Gauntlet Brauhaus in Killeen
Remote oxygen monitors used against Covid in Croydon
United States helps bolster Philippines’ capacity to combat wildlife crime
Turkey and Qatar set to remain close allies - the Economist
Cuba-Rushford's Bills Days raise funds for Buffalo hospital
UFC 257 -- Party with J.Lo, dinner with Bono, and the inside stories of Conor McGregor
Over a third of Swiss-bought Covid-19 vaccines have been administered
It Would Be Great to Have a Player Like Lionel Messi at Paris Saint-Germain
Priyanka Chopra shocked by 'bold' Nick Jonas when they first met
Priyanka Chopra Jonas and Adarsh Gourav on representation in The White Tiger
Saudi Arabia among top five countries in COVID-19 recovery index
IRClass Review of 2020 and Outlook for 2021 – The road to revitalisation
Met Office issues snow and ice warning for Herefordshire
Car collides head-on with Metrobus in DC
‘Netaji made the British nervous about Indian Army’ – Indian Defence Research Wing
Thin Places: Nature heals trauma in intricate Derry memoir
Roof And Floor Collapses In Washington Co. House Fire
One Day Left to File Provincial Election Papers
Merrillville starts process for bond issue
Dane County Sheriff's detectives arrest Middleton woman for Oklahoma homicide
Germany has set up hundreds of vaccination centres in sports halls and concert arenas and has the infrastructure to administer up to 300,000 shots a day, Health Minister Jens Spahn said."With the capacity we have already created in Germany, we will be able to carry out between 250,000 and 300,000 vaccinations per day - when we have the vaccine doses," Spahn said this week.Scarce vaccine supply, cumbersome paperwork, a lack of healthcare staff and an aged and immobile population are hampering efforts to get early doses of a vaccine made by U.(Graphic - COVID-19 vaccine doses administered: https://graphics.
3 million doses received.Spahn says manufacturing problems rather than too few orders are to blame for the limited supply, after Pfizer and BioNTech in December halved their production forecast to 50 million doses by year-end.